JP2013514811A - 免疫原性が抑制されたｂｍｐ−７変異体 - Google Patents

免疫原性が抑制されたｂｍｐ−７変異体 Download PDF

Info

Publication number
JP2013514811A
JP2013514811A JP2012546131A JP2012546131A JP2013514811A JP 2013514811 A JP2013514811 A JP 2013514811A JP 2012546131 A JP2012546131 A JP 2012546131A JP 2012546131 A JP2012546131 A JP 2012546131A JP 2013514811 A JP2013514811 A JP 2013514811A
Authority
JP
Japan
Prior art keywords
bmp
variant
protein
cell
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012546131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013514811A5 (https=
Inventor
マリリン エリザベス パターソン，
モーレイ ヒッチャム アラオウイ−イスマイリ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stryker Corp
Original Assignee
Stryker Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stryker Corp filed Critical Stryker Corp
Publication of JP2013514811A publication Critical patent/JP2013514811A/ja
Publication of JP2013514811A5 publication Critical patent/JP2013514811A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2012546131A 2009-12-22 2010-12-21 免疫原性が抑制されたｂｍｐ−７変異体 Pending JP2013514811A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28922009P 2009-12-22 2009-12-22
US61/289,220 2009-12-22
PCT/US2010/061437 WO2011087768A1 (en) 2009-12-22 2010-12-21 Bmp-7 variants with reduced immunogenicity

Publications (2)

Publication Number Publication Date
JP2013514811A true JP2013514811A (ja) 2013-05-02
JP2013514811A5 JP2013514811A5 (https=) 2014-01-09

Family

ID=43735952

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012546131A Pending JP2013514811A (ja) 2009-12-22 2010-12-21 免疫原性が抑制されたｂｍｐ−７変異体

Country Status (7)

Country Link
US (1) US20130190236A1 (https=)
EP (1) EP2516456A1 (https=)
JP (1) JP2013514811A (https=)
CN (1) CN102822197A (https=)
AU (1) AU2010341565A1 (https=)
CA (1) CA2785038A1 (https=)
WO (1) WO2011087768A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114432423A (zh) 2014-09-26 2022-05-06 拉金德拉·萨哈伊·巴特纳格尔 用于治疗疾病和病症的NFkB活性的抑制剂
US10130678B2 (en) 2014-12-29 2018-11-20 Bioventus, LLC. Systems and methods for improved delivery of osteoinductive molecules in bone repair
WO2019148140A2 (en) * 2018-01-26 2019-08-01 Wu Joseph C Implantable biomaterials that enhance stem cell survival and function

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008500816A (ja) * 2004-03-31 2008-01-17 ゼンコー・インコーポレイテッド 改善された性質を有するｂｍｐ−７変異体
WO2008051526A2 (en) * 2006-10-23 2008-05-02 Stryker Corporation Bone morphogenetic proteins
JP2009521220A (ja) * 2005-12-22 2009-06-04 セントカー・インコーポレーテツド Ｂｍｐ−７変異体組成物、方法および使用
WO2009086131A1 (en) * 2007-12-21 2009-07-09 Stryker Corporation Bmp mutants with decreased susceptibility to noggin

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US6919308B2 (en) 1988-04-08 2005-07-19 Stryker Corporation Osteogenic devices
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
JPH06500466A (ja) 1990-06-15 1994-01-20 カーネギー インスチチューション オブ ワシントン Ｇｄｆ―１
US5656593A (en) 1991-03-11 1997-08-12 Creative Biomolecules, Inc. Morphogen induced periodontal tissue regeneration
US5674844A (en) 1991-03-11 1997-10-07 Creative Biomolecules, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US6800603B2 (en) 1991-03-11 2004-10-05 Curis, Inc. Morphogen-induced neural cell adhesion
US5849686A (en) 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
US6506729B1 (en) 1991-03-11 2003-01-14 Curis, Inc. Methods and compositions for the treatment and prevention of Parkinson's disease
US6949505B1 (en) 1991-03-11 2005-09-27 Curis, Inc. Morphogen-induced dendritic growth
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
ATE238417T1 (de) 1991-11-04 2003-05-15 Inst Genetics Llc Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
DK0625989T3 (da) 1992-02-12 2000-06-26 Bioph Biotech Entw Pharm Gmbh DNA-sekvenser kodende for hidtil ukendte vækst-/differentieringsfaktorer
JPH08503198A (ja) 1992-11-03 1996-04-09 クリエイティブ バイオモレキュルズ，インコーポレイテッド Ｏｐ−３誘導形態形成
JP3645258B2 (ja) 1993-01-12 2005-05-11 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 増殖分化因子−５
EP0678101A4 (en) 1993-01-12 1997-07-16 Univ Johns Hopkins Med FACTOR-9 OF GROWTH AND DIFFERENTIATION.
DK0690873T3 (da) 1993-03-19 2003-09-29 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-8
BR9406715A (pt) 1993-05-12 1996-02-06 Genetics Inst Molécula de DNA isolada célula hospedeira vetor método para produzir uma proteina (BMP-11) polipeptideo de proteina-11 morfogenética de osso purificada (BMP-11) e molécula de DNA quimérica
EP0698095B1 (en) 1993-05-12 2004-04-28 Genetics Institute, LLC Bmp-10 compositions
CA2165776A1 (en) 1993-07-09 1995-01-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-6
EP0725796A4 (en) 1993-10-08 1999-12-01 Univ Johns Hopkins Growth differentiation factor-10
JP3300500B2 (ja) 1993-10-12 2002-07-08 新日本製鐵株式会社 疲労強度、降伏強度および被削性に優れる熱間鍛造用鋼の製造方法
DE4334646C1 (de) 1993-10-12 1994-09-29 Quinting Friedhelm Durchsichtige Analog-Zeituhr
US5399677A (en) 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
DE69434651T2 (de) 1993-12-07 2007-03-08 Genetics Institute, Inc., Cambridge Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
IL114397A0 (en) 1994-07-01 1995-10-31 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF-beta-family
CA2194660C (en) 1994-07-08 2009-09-29 Se-Jin Lee Growth differentiation factor-11
WO1996014335A1 (en) 1994-11-07 1996-05-17 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Health And Human Services Cartilage-derived morphogenetic proteins
US5635372A (en) 1995-05-18 1997-06-03 Genetics Institute, Inc. BMP-15 compositions
KR20000064752A (ko) 1996-03-22 2000-11-06 더 제네랄 호스피탈 코포레이션 중추신경계허혈또는외상의발현후폴리펩티드성장인자를투여하는방법
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US7041641B2 (en) 1997-03-20 2006-05-09 Stryker Corporation Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
US6958149B2 (en) 1998-10-06 2005-10-25 Stryker Corporation Repair of larynx, trachea, and other fibrocartilaginous tissues
US6846906B1 (en) 1998-10-07 2005-01-25 Stryker Corporation Modified proteins of the TGF-β superfamily, including morphogenic proteins
JP3762222B2 (ja) 1998-10-07 2006-04-05 ストライカー・コーポレーション 改変型ＴＧＦ−βスーパーファミリータンパク質
US6677432B1 (en) 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
US6949251B2 (en) 2001-03-02 2005-09-27 Stryker Corporation Porous β-tricalcium phosphate granules for regeneration of bone tissue
US8154581B2 (en) 2002-10-15 2012-04-10 Revolutionary Concepts, Inc. Audio-video communication system for receiving person at entrance
US8501424B2 (en) * 2003-11-03 2013-08-06 Danisco Us Inc. Cd4+ epitopes of bone morphogenetic proteins
WO2005113585A2 (en) 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
ES2369629T3 (es) 2004-05-25 2011-12-02 Stryker Corporation Uso de op-1 para tratar defectos del cartílago.
US7659250B2 (en) * 2005-12-22 2010-02-09 Centocor, Inc. BMP-7 variant compositions, methods and uses
WO2010117047A1 (ja) 2009-04-10 2010-10-14 株式会社ニコン 光学材料、光学素子、及びその製造方法
JP2011211450A (ja) 2010-03-30 2011-10-20 Victor Co Of Japan Ltd 立体映像表示装置、立体映像撮像装置および立体映像表示方法
US9507084B2 (en) 2010-12-03 2016-11-29 Ofs Fitel, Llc Single-mode, bend-compensated, large-mode-area optical fibers designed to accomodate simplified fabrication and tighter bends
US8886307B2 (en) 2012-01-30 2014-11-11 Medtronic, Inc. Adaptive cardiac resynchronization therapy
WO2013183270A1 (ja) 2012-06-07 2013-12-12 旭化成エレクトロニクス株式会社 位置検出装置
US9298469B2 (en) 2012-06-15 2016-03-29 International Business Machines Corporation Management of multiple nested transactions
US9405290B1 (en) 2013-01-17 2016-08-02 Kla-Tencor Corporation Model for optical dispersion of high-K dielectrics including defects
JP6154215B2 (ja) 2013-06-28 2017-06-28 株式会社日立国際電気 半導体装置の製造方法、基板処理装置およびプログラム
US9170581B2 (en) 2013-09-30 2015-10-27 Crown Equipment Limited Industrial vehicles with overhead light based localization
JP6541301B2 (ja) 2014-03-28 2019-07-10 キヤノン株式会社 ロボット装置、ロボット装置の制御方法、ロボット制御プログラム、及び記録媒体
US9411440B2 (en) 2014-08-22 2016-08-09 Qualcomm Incorporated Digital ultrasonic emitting base station
US9407762B2 (en) 2014-10-10 2016-08-02 Bank Of America Corporation Providing enhanced user authentication functionalities
US9412814B2 (en) 2014-12-24 2016-08-09 Taiwan Semiconductor Manufacturing Co., Ltd. Structure and formation method of FinFET device
US9400685B1 (en) 2015-01-30 2016-07-26 Huawei Technologies Co., Ltd. Dividing, scheduling, and parallel processing compiled sub-tasks on an asynchronous multi-core processor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008500816A (ja) * 2004-03-31 2008-01-17 ゼンコー・インコーポレイテッド 改善された性質を有するｂｍｐ−７変異体
JP2009521220A (ja) * 2005-12-22 2009-06-04 セントカー・インコーポレーテツド Ｂｍｐ−７変異体組成物、方法および使用
WO2008051526A2 (en) * 2006-10-23 2008-05-02 Stryker Corporation Bone morphogenetic proteins
WO2009086131A1 (en) * 2007-12-21 2009-07-09 Stryker Corporation Bmp mutants with decreased susceptibility to noggin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6015001594; ＡＬＡＯＵＩ-ＩＳＭＡＩＬＩ　ＭＨ　ｅｔ　ａｌ．，　Ｄｅｓｉｇｎ　ｏｆ　ｓｅｃｏｎｄ　ｇｅｎｅｒａｔｉｏｎ　ｔｈｅｒａｐｅｕｔｉｃ　ｒｅｃｏｍｂｉｎａｎｔ　ｂｏｎｅ　ｍｏｒｐｈｏｇｅｎｅｔｉｃ　ｐｒｏ *

Also Published As

Publication number Publication date
CA2785038A1 (en) 2011-07-21
WO2011087768A1 (en) 2011-07-21
EP2516456A1 (en) 2012-10-31
CN102822197A (zh) 2012-12-12
AU2010341565A1 (en) 2012-07-12
US20130190236A1 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
JP5529754B2 (ja) Ｎｏｇｇｉｎに対する感受性が低下したＢＭＰ変異体
TWI444475B (zh) 經設計之成骨蛋白類
US9200048B2 (en) High activity growth factor mutants
EP2352750B1 (en) Buffers for controlling the ph of bone morphogenetic proteins
JP2013514811A (ja) 免疫原性が抑制されたｂｍｐ−７変異体
US20110224138A1 (en) Methods for treating pain induced by injuries and diseases of an articular joint
RS58253B1 (sr) Mutant gdf-5 za indukciju formiranja hrskavice
US9012401B2 (en) Growth factor mutants with improved biological activity
JP2023530106A (ja) 細胞外マトリックスに結合するＩＬ－１受容体アンタゴニスト（ＩＬ－１Ｒａ）融合タンパク質
AU2017200239B2 (en) Designer osteogenic proteins
Jakob et al. tion in humans must be determined. In order to solve these issues, further experimental studies in large ani

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131111

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20141222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150617